Engflag

Neo Pectol

Quick links to important sections

Neo Pectol

Neo Pectol_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neo Pectol

Quick Facts

Property Description
Active Ingredient Codeine, Ipecac, Potassium Citrate, Squill
Form Oral Solution or Syrup
Pharmacological Class Antitussive and Expectorant Combination
Common Use Relief from cough and phlegm buildup
Origin Mixed (Semisynthetic opioid derivative, Plant extracts, Synthetic salt)

What is Neo Pectol?

Neo Pectol is a well-established fixed-dose combination medication classified as an antitussive and expectorant combination, formulated for the oral management of cough and associated respiratory symptoms. This preparation is typically supplied as an Oral Solution or Syrup for consumption. Its formulation is representative of traditional polypharmaceuticals, combining multiple active ingredients to offer a synergistic approach to symptom relief, addressing both the central urge to cough and the physical properties of respiratory secretions.

What Type of Medicine is Neo Pectol?

Neo Pectol is categorized by its dual action, designed to address both the severity of the cough reflex and the need for phlegm modification. The inclusion of Codeine classifies it as a narcotic antitussive. Codeine's antitussive activity is clinically recognized for its reliable action in reducing cough frequency and intensity, acting at the level of the brain's cough center. This type of combination, merging a centrally acting suppressant with botanically derived expectorants, is intended for use when a dry, irritating cough is accompanied by the difficulty of clearing viscous mucus.

Neo Pectol Composition: Active Ingredients and Origin

The product features four distinct active ingredients: Codeine, Ipecac, Potassium Citrate, and Squill, representing a mixed-origin formula. Codeine is a semisynthetic opioid derivative that provides the central cough suppression. The expectorant properties are largely contributed by the natural plant extracts Ipecac and Squill. Ipecac (from Carapichea ipecacuanha) contains alkaloids such as emetine, which are recognized for their secretolytic properties in low concentrations. The final component, Potassium Citrate, is a synthetic salt, primarily included as a systemic alkalizer to help modify the internal respiratory environment.

What is the General Purpose of Neo Pectol?

The general purpose of Neo Pectol is to provide comprehensive relief from cough associated with respiratory conditions by coordinating these two actions. The Codeine component acts centrally to diminish the drive to cough. Simultaneously, the Ipecac and Squill components function peripherally to promote the production of thinner, less viscous phlegm, thereby facilitating its clearance from the airways. This combination strategy aims to reduce the immediate discomfort of unproductive or disruptive coughing while assisting the patient's respiratory function.

What side effects are possible with Neo Pectol?

Possible side effects and safety information

The safety profile of this combination medicine is largely defined by the presence of Codeine, an opioid component. The adverse reactions are classified by frequency and body system, as documented in official regulatory labeling.

Adverse Reaction Categories

Commonly documented adverse reactions often involve the Central Nervous System (CNS) and the Gastrointestinal system. Effects frequently listed in regulatory summaries include drowsiness, dizziness, lightheadedness, nausea, vomiting, and constipation. Nausea and vomiting may lessen after initial exposure, while constipation is often noted as a persistent effect. These are generally categorized as expected adverse effects [NIH StatPearls].

Serious adverse reactions are explicitly documented in official labeling. The most critical risk is life-threatening respiratory depression and death, particularly associated with the opioid component. Official documents also confirm the risk of developing physical dependence, abuse, and misuse, which is associated with prolonged exposure [accessdata.fda.gov].

Population-Specific Safety Restrictions

Official safety documents include explicit restrictions for vulnerable groups. The medicine is strictly contraindicated in children younger than 12 years of age for any use, and also in adolescents under 18 years following tonsillectomy or adenoidectomy [TGA]. Additionally, the use is not recommended for breastfeeding mothers due to the risk of severe adverse events in the nursing infant [accessdata.fda.gov]. Older adults may also exhibit increased sensitivity to CNS effects, requiring careful consideration.

Time- and Condition-Related Safety Patterns

Regulatory information notes that the risk for severe respiratory depression is highest during the first 24 to 72 hours of treatment and following any dose increase. Furthermore, the use is restricted (contraindicated) in patients with pre-existing conditions such as significant respiratory depression, acute asthma, or gastrointestinal obstruction [accessdata.fda.gov].

Overdose and Emergency Response

Overdose and when to seek help

Overdose is officially documented to present with severe Central Nervous System (CNS) depression, including profound somnolence, stupor, and miosis (pinpoint pupils). The most critical, life-threatening manifestation is respiratory depression, potentially leading to apnea and respiratory arrest, specifically linked to the Codeine component. Further documented symptoms involve serious cardiotoxicity (arrhythmias, hypotension, conduction disturbances) from the Ipecac and Squill components, as well as severe gastrointestinal distress.

Due to these distinct and dangerous risks, immediate medical attention must be sought for any suspected overdose or upon the observation of symptoms such as profoundly altered consciousness, difficulty breathing, or cardiac irregularity. Overdose is officially classified as serious and potentially life-threatening, necessitating hospitalization for continuous monitoring, especially ECG monitoring for cardiac risk. The regulatory guidance mandates the administration of the opioid antagonist Naloxone for the Codeine-related effects, complemented by supportive care to manage all other manifestations, including electrolyte imbalances. Regulatory documents highlight an increased susceptibility to toxicity in pediatric patients and in the elderly or those with hepatic or renal impairment.

Therapeutic Uses of Neo Pectol

Quick Facts

  • Primary Use: Supports the temporary management of symptoms associated with specific forms of diarrhea.
  • Symptom Relief: Assists in firming the consistency of stools.
  • Associated Conditions: Used in the management of non-infectious, uncomplicated diarrhea.

Neo Pectol is a therapeutic option used for the supportive management of uncomplicated diarrhea. Its components assist in promoting a more solid stool consistency, which can help mitigate the associated temporary discomfort.

This compound is generally employed to help address acute, non-infectious gastrointestinal disturbances. The use of certain ingredients, such as Pectin, has been acknowledged for its adsorbent properties in managing symptoms associated with intestinal upset. Neo Pectol may be considered as a part of a wider strategy for managing digestive tract symptoms. It does not treat the underlying cause of the disturbance but rather addresses the manifestations of the condition. It is intended for temporary use and should be administered under professional guidance, especially if symptoms persist or worsen.

Eligibility and Restrictions for Use

Who Can and Cannot Use Neo Pectol?

The population eligibility for Neo Pectol is strictly regulated due to the inclusion of Codeine, an opioid antitussive. Regulatory guidelines establish specific populations for whom the medicine is contraindicated or subject to severe restriction.

Contraindicated Populations

Use of Neo Pectol is absolutely prohibited in the following groups:

  • Children younger than 12 years of age.
  • Women who are breastfeeding.
  • Patients who are known to be CYP2D6 ultra-rapid metabolizers.
  • Patients undergoing tonsillectomy or adenoidectomy for obstructive sleep apnea.
  • Individuals with acute respiratory depression or known hypersensitivity to any of the components.

Age and Condition Restrictions

Age Group / Condition Eligibility Status
Adolescents (12–18 years) Not recommended if respiratory function is compromised (e.g., severe lung disease, obesity).
Renal or Hepatic Impairment Use with caution is required.
Pregnancy Conditional use (long-term use is not recommended).

Eligibility is generally permitted for adults 18 years of age and older who do not have any contraindicating conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific pharmacokinetic and pharmacodynamic interactions for the components of Neo Pectol.

Contraindicated Combinations

Co-administration is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of potentiating opioid effects. The Codeine component's use requires a separation of at least 14 days after discontinuing an MAOI. The combination with Potassium-Sparing Diuretics (e.g., Triamterene) is also contraindicated because of the severe risk of hyperkalemia from the Potassium Citrate component. Due to the cardiac activity of Squill, co-administration with Cardiac Glycosides like Digoxin is strictly contraindicated.

Pharmacokinetic and Pharmacodynamic Effects

Interacting Substance Category Official Interaction Outcome
CYP2D6 Inhibitors (e.g., Quinidine) Decreased active metabolite (morphine) plasma concentration, leading to potential loss of efficacy.
CYP3A4 Inhibitors Increased Codeine (parent drug) plasma concentration.
CNS Depressants & Alcohol Risk of profound sedation and respiratory depression due to pharmacodynamic synergism.
NSAIDs & Potassium Salts Increased risk of hyperkalemia.

Population-Specific Constraints

The Codeine component is contraindicated in CYP2D6 ultra-rapid metabolizers due to the danger of elevated morphine levels. The Potassium Citrate component is also contraindicated in patients with impaired potassium excretion, such as those with chronic renal failure.

Mechanism of Action

️ How Neo Pectol Works

Central Neural Dampening of the Cough Signal

The antitussive mechanism centers on the Central Nervous System ( CNS), where the Codeine component acts as an agonist on mu- and kappa-opioid receptors located within the brain's cough center. This specific action raises the neural threshold required to trigger the cough reflex, directly modulating the central cough reflex arc. The resulting physiological effect is a modulation of efferent signaling from the central cough center.

Reflexive Enhancement of Bronchial Secretions

The expectorant action is initiated peripherally through reflexogenic stimulation of vagal nerve endings in the Gastric Mucosa by Ipecac and Squill alkaloids. This triggers the Gastro-Pulmonary Vagal Reflex , which efferently stimulates bronchial secretory cells. This mechanism leads to a physiological outcome of increased volume and decreased viscosity of respiratory secretions, which modifies the rheological properties of mucus.

Systemic Modulation of Respiratory Fluid Dynamics

Potassium Citrate introduces a subtle systemic alkalization mechanism. It is absorbed and metabolized in the liver to form bicarbonate ( HCO3^-), increasing the systemic buffering capacity. This change may promote the diffusion of water into the airways, contributing to the physicochemical modification of bronchial mucus fluidity.

Dosage and Administration Information

Neo Pectol is administered strictly via the oral route as a liquid solution or syrup. The usage protocol is defined by standardized protocols to ensure consistent use patterns and is primarily intended for short-term administration for acute symptoms.

Key instructions include specific dosing patterns and administration constraints:

Instruction Domain Standard Requirement
Route & Form Administered Orally only, requiring a calibrated milliliter measuring device for precise volume intake.
Adult Dosing & Frequency A single dose equivalent to 15 mg to 60 mg of Codeine is taken every 4 to 6 hours as needed, not exceeding 360 mg Codeine total in 24 hours.
Intake Condition Can generally be taken with or without food.
Missed Dose Rule If a dose is missed, it must be skipped if close to the next scheduled time; double doses must be avoided.

The administration schedule is strictly constrained by the maximum daily dose to prevent excessive intake over a 24-hour period.

A critical constraint involves age-based use: The product is contraindicated for use in children younger than 12 years of age for all indications. Use in older adolescents requires careful assessment. These precise instructions define the mandatory procedural structure for using the medicine.

Recent Clinical Evidence

Research into combination antitussive and expectorant medicines, which includes ingredients like codeine, has explored how these preparations are studied in relation to cough symptoms. Studies conducted during periods of increased symptom activity, such as coughs associated with respiratory infections, have monitored outcomes related to physical discomfort. Researchers focused on Randomized Controlled Trials (RCTs), where results are measured against a placebo, as well as broader systematic reviews. Outcomes examined included measurements of cough frequency, intensity, and patient-reported discomfort like sleep interference.

Findings from comprehensive reviews often indicate that the evidence for the main antitussive component (Codeine) in studies evaluating acute cough is limited and heterogeneous. Study follow-up durations were typically short-term (less than two weeks), providing insight into acute changes but not capturing sustained outcomes. For chronic cough, some observational evidence exists, but long-term health outcomes are not fully established, highlighting a major research gap.

The research has explored use in adult populations. However, data for certain groups remain insufficient. Regulatory assessments, including those from the European Medicines Agency and the U.S. Food and Drug Administration, have reviewed the available data and introduced restrictions regarding use in adolescents and children due to the limited supporting research for use in these age groups and regulatory concerns regarding safety. A key limitation is the lack of recent, dedicated RCTs specifically evaluating the precise fixed-dose combination of all four active ingredients together. Evidence quality varies, and limited evidence is available from comparative studies against other therapeutic options.

Key Studies & References Cough (acute): antimicrobial prescribing (NICE Guideline NG120)

Frequently Asked Questions (FAQ)

Common questions about Neo Pectol (FAQ)

Q: How quickly should I expect Neo Pectol to start working?

Official information indicates that the antitussive component, codeine, typically begins to have an effect within 15 to 45 minutes after the liquid is taken. The medicine usually reaches its peak concentration in the body within 1 to 2 hours. The strongest effects of the antitussive component are typically observed within that initial one-to-two-hour period, though individual response may vary.

Q: Does Neo Pectol interact with common painkillers like acetaminophen?

Regulatory documents note that products containing both codeine and acetaminophen (a common pain reliever) are subject to specific warnings. When taken together, there is a potential for increased sedation from the opioid component. Furthermore, caution is described as necessary, as exceeding recommended limits for acetaminophen, even in combination products, can increase the risk of liver toxicity.

Q: Are there any warnings about using Neo Pectol during pregnancy?

According to the official product information, the codeine component in Neo Pectol may cause harm to the fetus. If the medicine is used for an extended period during pregnancy, there is a risk that the baby may develop Neonatal Opioid Withdrawal Syndrome (NOWS) after birth. Due to this risk, official guidance includes warnings against use during pregnancy.

Q: Is Neo Pectol available without a prescription?

The codeine component of Neo Pectol is typically classified as a Controlled Substance in many regions. Official regulatory designation requires that products containing this ingredient are designated as prescription-only to ensure standardized dispensing and monitoring. Therefore, it is generally not available over the counter.

Q: Does Neo Pectol contain any ingredients that cause allergic reactions?

Regulatory documents advise that certain codeine-containing products may include inactive ingredients, such as sulfites, that have the potential to trigger allergic reactions in susceptible people. This warning is particularly relevant for individuals who have a history of asthma. For individuals with known allergies, reviewing the full inactive ingredient list is described as necessary.

Q: Can Neo Pectol be taken alongside herbal supplements?

Regulatory labeling states that individuals should discuss all medicines, including herbal supplements and vitamins, with a healthcare professional before starting Neo Pectol. This is necessary because some herbal ingredients can change how the medicine works or increase the risk of adverse effects due to interactions.

Q: Does Neo Pectol show up on common drug screening tests?

Yes, regulatory and clinical lab guidelines confirm that the medicine's codeine component is an opiate. Because of this, its presence, as well as the presence of its active metabolite, morphine, can be detected on standard drug screening tests.

Q: Is it normal to have a slight headache when starting Neo Pectol?

While common adverse reactions involve the central nervous system, such as drowsiness and dizziness, headaches have also been reported as an adverse reaction. This information is noted in the post-marketing experience sections of official regulatory summaries for codeine-containing products.

Q: Does Neo Pectol lose effectiveness over time with repeated use?

Official warnings and precautions sections for the opioid component (codeine) address the possibility of the body developing tolerance with prolonged or repeated use. This indicates that a person might require higher amounts of the medicine over time to achieve the same therapeutic effect.

Q: Can I stop using Neo Pectol as soon as my symptoms improve?

Safety information for opioids includes warnings that if the medicine has been used for an extended period, suddenly stopping it may result in withdrawal symptoms. Official safety information states that any changes to the use of the medicine, including discontinuation, are typically addressed by a healthcare provider.

Q: Why do official documents mention certain liver conditions as a contraindication?

Official drug information for codeine often includes warnings regarding conditions such as liver disease. This is primarily because the drug is metabolized (broken down) in the liver. Impaired liver function can affect how the body processes the medicine, which may increase its effects or potentially lead to liver damage.

Q: Does Neo Pectol have any specific warnings for people with diabetes?

While not a direct contraindication, official regulatory summaries have noted potential effects on blood sugar levels from similar medications. Specifically, an increase in blood glucose has been reported in some patients, and this potential change in blood glucose is noted in regulatory summaries.

Q: Is it better to take Neo Pectol in the morning or the evening?

Regulatory information notes that due to the potential for drowsiness and dizziness, timing the dose to minimize daily impairment may be a factor in use. This could mean adjusting the time of day, though specific guidance on morning or evening use is not universally defined in official labeling.

Q: Does Neo Pectol contain sugar or gluten?

Official product descriptions for oral solutions indicate that most syrups contain sugar as an inactive ingredient. The full inclusion of other components like gluten depends on the specific manufacturer and formula, and this information is found in the complete inactive ingredient list.

How should Neo Pectol be stored and disposed of?

Storage and Disposal Conditions for Neo Pectol

Storage and disposal requirements for Neo Pectol are determined by its formulation as a Codeine-containing oral solution, classified as a Controlled Substance.

Area
Storage Temperature The product must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), protected from freezing and excess heat or moisture.
Container Security Keep the medicine in its original container and ensure the cap remains tightly closed. Store the product securely to prevent access by unauthorized persons.
Child Protection Mandatory: Keep the medication out of the sight and reach of children. Accidental ingestion of opioid-containing medicine can be fatal to a child.
Disposal Instructions Unused or expired medication should be discarded via an authorized drug take-back program. If a program is not available, official guidance often permits the immediate flushing of opioids to prevent accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Neo Pectol found in:

A-Z Index: